Advertisement
Australia markets closed

  • ALL ORDS

    7,970.80
    +74.90 (+0.95%)
     

  • ASX 200

    7,701.70
    +73.50 (+0.96%)
     

  • AUD/USD

    0.6655
    +0.0021 (+0.31%)
     

  • OIL

    77.18
    -0.73 (-0.94%)
     

  • GOLD

    2,347.70
    -18.80 (-0.79%)
     

  • Bitcoin AUD

    101,700.70
    +728.85 (+0.72%)
     

  • CMC Crypto 200

    1,421.45
    -7.12 (-0.50%)
     

  • AUD/EUR

    0.6132
    +0.0014 (+0.23%)
     

  • AUD/NZD

    1.0824
    -0.0020 (-0.19%)
     

  • NZX 50

    11,867.29
    +310.08 (+2.68%)
     

  • NASDAQ

    18,536.65
    -2.01 (-0.01%)
     

  • FTSE

    8,275.38
    +44.33 (+0.54%)
     

  • Dow Jones

    38,686.32
    +574.84 (+1.51%)
     

  • DAX

    18,497.94
    +1.15 (+0.01%)
     

  • Hang Seng

    18,079.61
    -150.58 (-0.83%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

Xenetic Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

editorial-team@simplywallst.com (Simply Wall St)
·1-min read

Xenetic Biosciences (NASDAQ:XBIO) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$510.8k (down 16% from 1Q 2023).

  • Net loss: US$1.20m (loss widened by 40% from 1Q 2023).

  • US$0.78 loss per share (further deteriorated from US$0.56 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xenetic Biosciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 1.3%.

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are down 8.8% from a week ago.

Risk Analysis

Be aware that Xenetic Biosciences is showing 5 warning signs in our investment analysis and 2 of those are a bit unpleasant...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.